Piramal Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 15, 2026
- Posted by: Harsh Piplani
- Category: Results
Piramal Pharma share price Rs 211.35 on 15 September 2026, up 0.00%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 69.00 crore loss. Q2 FY26 base a loss of Rs 99.00 crore.
Quick Answer
The Piramal Pharma Q2 results date for FY27 is not confirmed, and Piramal Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 2,044.00 crore in revenue and a loss of Rs 99.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Piramal Pharma Q2 results FY27 announcement is the next scheduled earnings event for Piramal Pharma Ltd., a pharmaceutical group spanning contract development and manufacturing (CDMO), hospital generics and critical care, and consumer health and wellness brands. The stock traded at Rs 211.35 on the NSE on 15 September 2026, up 0.00% from the previous close of Rs 211.35, about 8.9% below its 52-week high of Rs 231.93 and 59.8% above its 52-week low of Rs 132.30.
What makes the Piramal Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 2,044.00 crore of revenue and a loss of Rs 99.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 2,270.00 crore and a loss of Rs 69.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Piramal Pharma Q2 Results FY27 Date?
The Piramal Pharma Q2 results date for FY27 is not confirmed. As of 15 September 2026, Piramal Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Piramal Pharma Q2 results date becomes public through that filing rather than through any advance announcement.
The Piramal Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Piramal Pharma.
Piramal Pharma Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Piramal Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Piramal Pharma. The Piramal Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.
Piramal Pharma’s consolidated revenue rose from Rs 1,934 crore in June 2025 to Rs 2,044 crore in September 2025, Rs 2,140 crore in December 2025, Rs 2,752 crore in March 2026, and Rs 2,270 crore in June 2026. This consistent top-line growth across the five quarters shown is a trend investors will be tracking into the September 2026 quarter.
Despite that revenue growth, the company has posted a net loss in every one of the five quarters shown: a net loss of Rs 82 crore in June 2025, a net loss of Rs 99 crore in September 2025, a net loss of Rs 136 crore in December 2025, a net loss of Rs 9 crore in March 2026, and a net loss of Rs 69 crore in June 2026. This is a pattern of sustained net losses rather than a story of improving bottom-line profitability, and whether the loss narrows or widens will be a key data point in the upcoming quarter.
Operating margin improved from 6% in June 2025 to 8% in September 2025, 9% in December 2025 and a notably higher 17% in March 2026 (operating profit of Rs 461 crore), before easing back to 9% in June 2026. The March 2026 spike stands out versus the surrounding quarters and may reflect a seasonal or one-off CDMO order rather than a new sustained margin level, so it is worth treating with caution as a comparison base for September 2026.
Check Piramal Pharma Ltd. Live Fundamentals on the Univest Screener
Piramal Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Piramal Pharma Ltd. reported revenue of Rs 2,270.00 crore in Q1 FY27, up 17.37% from Rs 1,934.00 crore in Q1 FY26, and a loss of Rs 69.00 crore at the net level, a narrower loss than the Rs 82.00 crore loss of Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 17.51% over the March 2026 quarter figure of Rs 2,752.00 crore, and net profit was a wider loss than the Rs 9.00 crore loss of Q4 FY26. Operating margin stood at 9.0% in Q1 FY27 against 8.0% in the September 2025 quarter, which is the comparison the Piramal Pharma Q2 results print will be read against.
Q2 FY26 Base: The Comparison Piramal Pharma Q2 Results FY27 Must Beat
Piramal Pharma Ltd. reported revenue of Rs 2,044.00 crore and a loss of Rs 99.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Piramal Pharma Q2 results preview.
Because the base quarter itself was loss-making, a year-on-year percentage comparison of profit is not meaningful for Piramal Pharma. The more useful test in the Piramal Pharma Q2 results print is whether the company reports a profit at all, and how the income line of Rs 2,044.00 crore compares with the Rs 2,270.00 crore of the June 2026 quarter.
Piramal Pharma Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 2,044.00 | (99.00) |
| Q3 FY26 (Dec 2025) | 2,140.00 | (136.00) |
| Q4 FY26 (Mar 2026) | 2,752.00 | (9.00) |
| Q1 FY27 (Jun 2026) | 2,270.00 | (69.00) |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Piramal Pharma Q2 results preview uses.
Revenue across those four quarters ranged from Rs 2,044.00 crore to Rs 2,752.00 crore, and net profit from Rs 136.00 crore loss to Rs 9.00 crore loss. That spread is the honest context for the Piramal Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Piramal Pharma Q2 Results FY27
The Piramal Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Piramal Pharma has already reported.
Loss-Making Status Keeps P/E Not Meaningful
With the company loss-making on a trailing basis, its P/E is not meaningful, while price-to-book stands at about 3.44 times and return on equity is negative 3.83%. These figures reflect a company still working toward consistent profitability rather than one that can be assessed on earnings multiples alone.
FII Holding Fell Sharply in the June 2026 Quarter
Foreign institutional investor holding in the company dropped from about 30.17% to around 12.51% in the June 2026 quarter, while public shareholding rose to 37.62% over the same period. This is a factual ownership shift worth noting as background context for the September 2026 quarter, separate from the company’s operating performance.
Stock Trades Near Its 52-Week High
The current price of Rs 211.35 is close to its 52-week high of Rs 231.93 and well above its 52-week low of Rs 132.3, trading above both its 50-day moving average of Rs 199.58 and 200-day moving average of Rs 172.65, with an RSI of 50.20, a neutral reading.
Piramal Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print
Piramal Pharma share price today is Rs 211.35 on the NSE, up Rs 0.00 or 0.00% from the previous close of Rs 211.35 on 15 September 2026, ahead of the Piramal Pharma Q2 results announcement.
| Metric | Value (15 September 2026) |
|---|---|
| NSE Symbol | PPLPHARMA |
| Current Market Price | Rs 211.35 |
| 52-Week High | Rs 231.93 |
| 52-Week Low | Rs 132.30 |
| Market Capitalisation | Rs 28,138 crore |
| PE Ratio | Not meaningful on a trailing loss |
| PB Ratio | 3.44 |
| EPS (TTM) | Not meaningful on a trailing loss |
| Book Value per Share | Rs 61.40 |
| Debt to Equity | 0.70 |
| Return on Equity | -3.83% |
| 50-Day Moving Average | Rs 199.58 |
| 200-Day Moving Average | Rs 172.65 |
| RSI (14) | 50.20 |
The stock trades above both its 50-day average of Rs 199.58 and its 200-day average of Rs 172.65, with a 14-day RSI of 50.20. None of this is a view on where the shares go once the Piramal Pharma Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Piramal Pharma Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Piramal Pharma Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Piramal Pharma Q2 results print in proportion.
- Revenue against the Rs 2,044.00 crore reported in the September 2025 base quarter
- Net profit against a loss of Rs 99.00 crore in that same quarter
- Operating margin against 9.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Piramal Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Piramal Pharma Q2 Results FY27
The Piramal Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Piramal Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Piramal Pharma Q2 results FY27 print faces a base of Rs 2,044.00 crore in revenue and a loss of Rs 99.00 crore, with the most recent quarter having delivered Rs 2,270.00 crore and a loss of Rs 69.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Piramal Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Piramal Pharma Q2 Results FY27
What is the Piramal Pharma Q2 results date for FY27?
Ans. The Piramal Pharma Q2 results date for FY27 is not confirmed. Piramal Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Piramal Pharma Q2 results 2026 cover?
Ans. The Piramal Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Piramal Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Piramal Pharma Q2 results filing also carries the notes to the accounts.
What were the Piramal Pharma Q1 FY27 results?
Ans. Piramal Pharma Ltd. reported revenue of Rs 2,270.00 crore in Q1 FY27 and a loss of Rs 69.00 crore at the net level. Revenue was up 17.37% versus Q1 FY26 and net profit was a narrower loss than the Rs 82.00 crore loss of Q1 FY26.
What were Piramal Pharma Q2 FY26 results in the September 2025 quarter?
Ans. Piramal Pharma Ltd. reported revenue of Rs 2,044.00 crore and a loss of Rs 99.00 crore in Q2 FY26. Operating margin was 8.0%. Those figures form the base for the Piramal Pharma Q2 results FY27 comparison.
What are the main Piramal Pharma Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Piramal Pharma Q2 results expectations centre on revenue against the Rs 2,044.00 crore base, net profit against a loss of Rs 99.00 crore, operating margin against 9.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Piramal Pharma share price today ahead of the Q2 earnings?
Ans. Piramal Pharma share price is Rs 211.35 on the NSE as of 15 September 2026, up 0.00% from Rs 211.35. The stock is about 8.9% below its 52-week high of Rs 231.93 and 59.8% above its 52-week low of Rs 132.30, at a market capitalisation of Rs 28,138 crore.
Is Piramal Pharma a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Piramal Pharma Ltd. The stock trades at a price-to-book ratio of 3.44 with a return on equity of -3.83%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
